Keros Therapeutics Q2 2023 Earnings Report $15.64 -0.46 (-2.86%) As of 01/6/2025 04:00 PM Eastern Earnings HistoryForecast Keros Therapeutics EPS ResultsActual EPS-$1.27Consensus EPS -$1.34Beat/MissBeat by +$0.07One Year Ago EPS-$1.13Keros Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.22 millionBeat/MissN/AYoY Revenue GrowthN/AKeros Therapeutics Announcement DetailsQuarterQ2 2023Date8/7/2023TimeBefore Market OpensConference Call ResourcesPress ReleaseSEC FilingKROS Earnings HistoryPowered by Man Who Called Nvidia Says: “Your Retirement Is Inside This Building.” (Ad)In 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $3 trillion company... And the stock is up massively since Jeff's recommendation. Now, Jeff has found five under-the-radar stocks which could power your retirement. Keros Therapeutics Earnings HeadlinesBank of America Securities Sticks to Its Buy Rating for Keros Therapeutics (KROS)January 6 at 11:23 PM | markets.businessinsider.comKeros Therapeutics (NASDAQ:KROS) Reaches New 52-Week Low - Should You Sell?January 1, 2025 | americanbankingnews.comTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… January 7, 2025 | Crypto 101 Media (Ad)SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. ...December 28, 2024 | gurufocus.comAnalyst’s Buy Rating on Keros Therapeutics Driven by Strategic Partnerships and Market PotentialDecember 23, 2024 | markets.businessinsider.comKeros Therapeutics: Trading At Essentially Cash Value, Target Of $23 Per ShareDecember 18, 2024 | seekingalpha.comSee More Keros Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Keros Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Keros Therapeutics and other key companies, straight to your email. Email Address About Keros TherapeuticsKeros Therapeutics (NASDAQ:KROS), a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.View Keros Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles S&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
